Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HR+/HER2- metastatic disease

- PMLiVE

Gilead’s COVID-19 treatment shows promising results in vulnerable patient populations

Veklury demonstrated a reduction in mortality and hospital readmission rates

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE for breast and prostate cancer

An estimated 800 patients will now be eligible for treatment with the drug

- PMLiVE

Eli Lilly’s Verzenio label expanded by FDA for early breast cancer patients

The decision removes the previous 20% Ki-67 score requirement for patient selection

- PMLiVE

Gilead reports positive real-world evidence for COVID-19 treatment Veklury

A study of more than 500,000 hospitalised patients showed a reduction in mortality risk

- PMLiVE

Gilead’s Trodelvy shows promise in phase 2 bladder cancer study

An estimated 83,000 Americans will be diagnosed with bladder cancer in 2023

- PMLiVE

Gilead’s Trodelvy approved by FDA for metastatic breast cancer

HR+/HER2- is the most common type of breast cancer, accounting for 70% of new cases

- PMLiVE

World Health Organization releases new road map for breast cancer

Nearly 80% of breast and cervical cancer deaths occur in low- and middle-income countries

- PMLiVE

First UK proton beam therapy trial launches for certain breast cancer patients

The trial will assess the therapy in patients at risk of heart problems after standard radiotherapy

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu recommended by NICE for advanced breast cancer

The treatment has been recommended for use within a managed access arrangement

- PMLiVE

Exact Sciences highlights impact of precision oncology portfolio on breast cancer treatment

Data presented at SABCS 2022 supports the company’s cancer diagnostics portfolio

- PMLiVE

Gilead announces positive new data for Trodelvy in metastatic breast cancer

The treatment demonstrated consistent efficacy across Trop-2 expression levels

- PMLiVE

Gilead’s Biktarvy received EC approval for the treatment of HIV in paediatric populations

After changing to Biktarvy, 98% of patients in two groups were suppressed at week 48

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links